PHI with Endocarditis parietalis fibroplastica (Löffler)
How does this condition affect your private health insurance?
Löffler's endocarditis, or Endocarditis parietalis fibroplastica, is a rare and severe form of restrictive cardiomyopathy characterized by significant eosinophilic infiltration of the endocardium, the inner lining of the heart chambers. This infiltration leads to myonecrosis, inflammation, and subsequent irreversible fibrosis, primarily affecting the ventricular apices and inflow tracts. It impairs ventricular filling, leading to diastolic dysfunction and ultimately severe heart failure. Often associated with hypereosinophilic syndrome, its exact pathophysiology involves the release of toxic granule contents from eosinophils, causing tissue damage. Early diagnosis and management of eosinophilia are crucial to prevent progressive cardiac damage.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Weeks to months, sometimes with acute onset of symptoms progressing rapidly.
Duration of Illness (Lifetime)
Chronic, progressive, potentially life-long if untreated, often leading to advanced heart failure.
Cost of Treatment (Initial)
High; typically tens of thousands to hundreds of thousands of USD for initial diagnosis, hospitalization, and acute management (e.g., echocardiography, cardiac MRI, biopsy, immunosuppression).
Cost of Treatment (Lifetime)
Very high; potentially hundreds of thousands to millions of USD, including long-term medication, regular cardiac monitoring, management of heart failure complications, and potentially cardiac transplantation.
Mortality Rate
High; estimated mortality rates range from 20-50% within 5 years, even with treatment, primarily due to progressive heart failure and complications.
Risk of Secondary Damages
High; includes severe heart failure, valvular dysfunction, arrhythmias, pulmonary hypertension, and systemic thromboembolic events due to endocardial thickening and mural thrombi formation.
Probability of Full Recovery
Very low; complete recovery without residual cardiac damage is rare, as established fibrosis is largely irreversible. Treatment aims to halt progression and manage symptoms.
Underlying Disease Risk
High; primarily associated with hypereosinophilic syndrome (HES) or other underlying disorders causing persistent eosinophilia (e.g., parasitic infections, malignancies, allergic conditions).